Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.

Shariati, Maryam; Evans, Kurt W; Zheng, Xiaofeng; Bristow, Christopher A; Ng, Patrick Kwok-Shing; Rizvi, Yasmeen Q; Tapia, Coya; Yang, Fei; Carugo, Alessandro; Heffernan, Timothy P; Peoples, Michael D; Tripathy, Debu; Meric-Bernstam, Funda

Shariati, Maryam; Evans, Kurt W; Zheng, Xiaofeng; Bristow, Christopher A; Ng, Patrick Kwok-Shing; Rizvi, Yasmeen Q; Tapia, Coya; Yang, Fei; Carugo, Alessandro; Heffernan, Timothy P; Peoples, Michael D; Tripathy, Debu; Meric-Bernstam, Funda.

Afiliación

Shariati M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zheng X; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bristow CA; Center for Co-Clinical Trials and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ng PK; The Sheikh Khalifa Bin Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rizvi YQ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tapia C; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yang F; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carugo A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Heffernan TP; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peoples MD; Center for Co-Clinical Trials and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tripathy D; Center for Co-Clinical Trials and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Meric-Bernstam F; Center for Co-Clinical Trials and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Oncogene ; 40(26): 4425-4439, 2021 07.

Article en En | MEDLINE | ID: mdl-34108622

Asunto(s)

Neoplasias de la Mama/genética; Fosfatidilinositol 3-Quinasa Clase I/genética; Quinasas Ciclina-Dependientes/antagonistas & inhibidores; Receptor con Dominio Discoidina 1/antagonistas & inhibidores; Proteínas Proto-Oncogénicas c-akt/genética; Receptor ErbB-2/genética; Receptores de Estrógenos/genética; Animales; Protocolos de Quimioterapia Combinada Antineoplásica/farmacología; Neoplasias de la Mama/tratamiento farmacológico; Puntos de Control del Ciclo Celular/efectos de los fármacos; Puntos de Control del Ciclo Celular/genética; Línea Celular Tumoral; Proliferación Celular/efectos de los fármacos; Proliferación Celular/genética; Femenino; Humanos; Células MCF-7; Mutación/genética; Inhibidores de Proteínas Quinasas/farmacología; Transducción de Señal/efectos de los fármacos; Transducción de Señal/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Estrógenos / Receptor ErbB-2 / Quinasas Ciclina-Dependientes / Proteínas Proto-Oncogénicas c-akt / Fosfatidilinositol 3-Quinasa Clase I / Receptor con Dominio Discoidina 1 Límite: Animals / Female / Humans Idioma: En Revista: Oncogene Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google